Evaluation of Serological Techniques for Screening for COVID-19 Infection at the University Hospital of Rouen

Protocol for the Collection of Clinical Samples for Evaluation and Implementation of Serological Techniques for Screening for COVID-19 Infection at the University Hospital of Rouen

Sponsors

Lead Sponsor: University Hospital, Rouen

Source University Hospital, Rouen
Brief Summary

At present, the offer of tests for the serological diagnosis of CoVID-19 (detection of IgG, IgM or IgA antibodies against CoV-2 SARS) is plethoric and is based on the use of a very large number of rapid diagnostic unit tests, a few dedicated high throughput automated systems or reagents on existing open systems. The offer will continue to expand in the coming months. In order to meet the objectives mentioned by the Prime Minister, and confirmed in the HAS report of April 16, 2020 and in the opinion n°6 of the COVID-19 scientific council concerning the potential use of these serological tests at the end of the COVID-19 epidemic, the Virology laboratory wishes to validate the sensitivity and specificity of the tests it intends to use.

Overall Status Recruiting
Start Date 2020-11-26
Completion Date 2023-12-01
Primary Completion Date 2023-12-01
Phase N/A
Study Type Interventional
Primary Outcome
Measure Time Frame
Evaluation of immunological Abbott Architect SARS-CoV-2 IgG Assay 24 months
Secondary Outcome
Measure Time Frame
Evaluation of immunological of EUROIMMUN SARS-CoV-2(IgA) ELISA, EUROIMMUN SARS-CoV-2 (IgG) ELISA, WANTAI SARS-CoV-2 Ab ELISA, WANTAI SARS-CoV-2 IgM ELISA, Diasorin LIAISON SARS CoV-2 S1/S2 IgG, Roche ECL anti-SARS-Cov-2 (combined IgG IgA) 24 months
Enrollment 385
Condition
Intervention

Intervention Type: Diagnostic Test

Intervention Name: Serological testing for COVID-19 infection

Description: The tests used will be the following: EUROIMMUN SARS-CoV-2(IgA) ELISA ELISA SARS-CoV-2 (IgG) EUROIMMUN WANTAI SARS-CoV-2 Ab ELISA WANTAI SARS-CoV-2 IgM ELISA Abbott Architect SARS-CoV-2 IgG Diasorin SARS LINK CoV-2 S1/S2 IgG Roche ECL anti-SARS-Cov-2 (combined IgG IgM IgA)

Arm Group Label: Patient infected or cured from covid19

Eligibility

Criteria:

Inclusion Criteria: The inclusion criteria in the retrospective "Negative/Potentially Interfering" group are as follows : - Adult patient sampled prior to the onset of the COVID-19 epidemic (before January 2020) - Patient presenting a coronavirus infection other than SARS-CoV-2, or other respiratory viral infections (influenza, metapneumovirus) - Patients for whom a serum is kept in the biocollection declared under the number AC-2014-2293 and kept in the Institute of Clinical Biology, University Hospital of Rouen. The criteria for inclusion in the "acute point infection" group are as follows: - Patients screened by a positive RT-PCR for an SARS-CoV-2 infection - Patients aged ≥ 18 years old - Patients taken in charge in the emergency room / in a unit / in COVID resuscitation at the Rouen University Hospital. - Patients having read and understood the briefing note - Non-opposition to participation in the study The criteria for inclusion in the "Sequential acute infection" group are as follows: - Patients with positive RT-PCR for CoV-2-SARS infection - Patients aged ≥ 18 years old - Taken care of in a COVID unit at the Rouen University Hospital - Having read and understood the briefing note and signed the informed consent form The criteria for inclusion in the "Convalescent" group are as follows: - Caregivers working at the UH of Rouen - Screened by positive RT-PCR for SARS-CoV-2 infection, - Healed for at least one month at the time of inclusion - Having read and understood the briefing note and signed the informed consent form Exclusion Criteria: - Minor person - Known Pregnancy - Person deprived of liberty by an administrative or judicial decision or person placed under judicial protection / subtutorship or guardianship - Person not affiliated with social security - Person who does not understand and speak French

Gender:

All

Minimum Age:

18 Years

Maximum Age:

80 Years

Healthy Volunteers:

No

Overall Contact

Last Name: Jean-Christophe Plantier, Professor

Phone: 02 32 88 66 72

Email: [email protected]

Location
Facility: Status: Contact: Contact Backup: Rouen University Hospital David Mallet
Location Countries

France

Verification Date

2021-01-01

Responsible Party

Type: Sponsor

Has Expanded Access No
Condition Browse
Number Of Arms 1
Arm Group

Label: Patient infected or cured from covid19

Type: Experimental

Description: Patients with an acute SARS-CoV-2 infection confirmed by a positive RT-PCR, hospitalized in COVID units or in COVID resuscitations, Nurses at the Rouen University Hospital infected with COVID 19, and cured, Patients with a high suggestive clinic for COVID-19 infection but with negative COVID-19 RT-PCR

Acronym SeroCOV
Study Design Info

Allocation: N/A

Intervention Model: Single Group Assignment

Primary Purpose: Diagnostic

Masking: None (Open Label)

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact [email protected]. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Research News